CG Oncology Phase 3 BOND-003: cretostimogene achieves 75.2% complete response in high-risk NMIBC

CG Oncology, Inc.

75.2% complete response (79/105 patients; 95% CI: 65-83) at any time in BCG-unresponsive high-risk NMIBC.
29 patients maintained CR for ≥12 months; median duration of response not reached as of April 1, 2024.
92.4% cystectomy-free-survival; no CR patient had radical cystectomy or nodal/metastatic progression.
No Grade 3+ TRAEs; 1.8% serious TRAEs (Grade 2 cystitis, clot retention); no treatment discontinuations.
Topline data from fully enrolled Phase 3 BOND-003 expected by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.